FDA Approves New SynchroMed II myPTM Personal Therapy Manager

Medical Device Investing

Medtronic (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the new SynchroMed II myPTM Personal Therapy Manager for patients with chronic pain. This device enables patients to alleviate their unpredictable pain by delivering on-demand boluses, or drug doses, within therapeutic limits set by their physician. As quoted in the press release: myPTMworks …

Medtronic (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the new SynchroMed II myPTM Personal Therapy Manager for patients with chronic pain. This device enables patients to alleviate their unpredictable pain by delivering on-demand boluses, or drug doses, within therapeutic limits set by their physician.

As quoted in the press release:

myPTMworks with the SynchroMedII Intrathecal Drug Delivery system, also known as a Medtronic pain pump, which delivers medication directly to the fluid around the spinal cord to relieve chronic pain in appropriate patients. The Medtronic pain pump, an implantable drug pump, provides long-term pain relief at lower doses and with fewer side effects compared to oral pain medications and may allow some patients to eliminate the use of systemic opioids.1, 3, 4, 8, 9 Personalization of the therapy gives patients the ability to alleviate unpredictable pain and may further reduce the need for oral opioids.8

“Pain is very personal and can be unpredictable. myPTM is a simple, easy-to-use device that allows my patients to personalize their treatment based on their day-to-day needs,” said John A. Hatheway, M.D., owner and provider at Northwest Pain Care in Spokane, Wash. “Enabling patients to adjust their treatment provides them with some independence to control their pain and gives me confidence knowing that they are getting pain relief without oral opioids. The Medtronic pain pump and myPTM are powerful tools to safely treat chronic pain including intractable cancer pain.”

Click here to read the full press release.

The Conversation (0)
Ă—